Bingliang Chen

1.6k total citations
47 papers, 1.1k citations indexed

About

Bingliang Chen is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Bingliang Chen has authored 47 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Molecular Biology and 12 papers in Immunology. Recurrent topics in Bingliang Chen's work include Cancer Immunotherapy and Biomarkers (11 papers), Ferroptosis and cancer prognosis (8 papers) and CAR-T cell therapy research (7 papers). Bingliang Chen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Ferroptosis and cancer prognosis (8 papers) and CAR-T cell therapy research (7 papers). Bingliang Chen collaborates with scholars based in China, United States and Germany. Bingliang Chen's co-authors include Alan P. Wolffe, Edward J. Rebar, Yuxin Liang, Casey C. Case, S. Kaye Spratt, Andrew C. Jamieson, Zhihai Wu, Weiwei Wu, Junjian Liu and Shuaixiang Zhou and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Nature Communications.

In The Last Decade

Bingliang Chen

43 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bingliang Chen China 17 524 385 281 114 103 47 1.1k
Hui Zeng China 17 397 0.8× 357 0.9× 234 0.8× 168 1.5× 157 1.5× 61 1.1k
Irena Radovanovic Canada 14 391 0.7× 211 0.5× 350 1.2× 111 1.0× 77 0.7× 16 1.1k
Tae Hyun Hwang United States 17 503 1.0× 300 0.8× 116 0.4× 129 1.1× 109 1.1× 49 992
Yalai Bai United States 20 455 0.9× 426 1.1× 284 1.0× 122 1.1× 175 1.7× 37 1.1k
Robyn D. Gartrell United States 18 221 0.4× 472 1.2× 297 1.1× 118 1.0× 116 1.1× 45 842
Aibin Liang China 19 689 1.3× 498 1.3× 202 0.7× 103 0.9× 65 0.6× 117 1.5k
Ting Zhuang China 20 800 1.5× 365 0.9× 115 0.4× 124 1.1× 67 0.7× 53 1.2k
Anita K. Mehta United States 12 442 0.8× 457 1.2× 345 1.2× 118 1.0× 80 0.8× 20 970
Julia Gilhodes France 19 513 1.0× 459 1.2× 309 1.1× 170 1.5× 78 0.8× 38 1.2k
Yingtao Bi United States 20 626 1.2× 211 0.5× 158 0.6× 87 0.8× 206 2.0× 41 1.3k

Countries citing papers authored by Bingliang Chen

Since Specialization
Citations

This map shows the geographic impact of Bingliang Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bingliang Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bingliang Chen more than expected).

Fields of papers citing papers by Bingliang Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bingliang Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bingliang Chen. The network helps show where Bingliang Chen may publish in the future.

Co-authorship network of co-authors of Bingliang Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Bingliang Chen. A scholar is included among the top collaborators of Bingliang Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bingliang Chen. Bingliang Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hu, Peng, Kang Liu, Wenchao Xu, et al.. (2024). MiRNA‐100 ameliorates diabetes mellitus‐induced erectile dysfunction by modulating autophagy, anti‐inflammatory, and antifibrotic effects. Andrology. 12(6). 1280–1293. 11 indexed citations
3.
Cheng, Bisheng, Haixia He, Bingliang Chen, et al.. (2024). Assessment of treatment outcomes: cytoreductive surgery compared to radiotherapy in oligometastatic prostate cancer – an in-depth quantitative evaluation and retrospective cohort analysis. International Journal of Surgery. 110(6). 3190–3202. 7 indexed citations
4.
Zhang, Zhimin, Li Li, Zhihai Wu, et al.. (2024). Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models. Cancer Immunology Immunotherapy. 73(5). 81–81. 2 indexed citations
5.
Wang, Chang, et al.. (2023). Dual-Functional Tunable Metasurface for Meta-Axicon with a Variable Depth of Focus and Continuous-Zoom Metalens. Nanomaterials. 13(18). 2530–2530. 1 indexed citations
6.
Zeng, Kai, Qinyu Li, Xi Wang, et al.. (2023). STX4 as a potential biomarker for predicting prognosis and guiding clinical treatment decisions in clear cell renal cell carcinoma. Heliyon. 10(1). e23918–e23918. 2 indexed citations
7.
Jin, Meng, Bo Liu, Yongbiao Huang, et al.. (2023). Genome-Wide Splicing Quantitative Expression Locus Analysis Identifies Causal Risk Variants for Non–Small Cell Lung Cancer. Cancer Research. 83(10). 1742–1756. 10 indexed citations
8.
Wu, Lin, Yingzi Zhang, Yan Yang, et al.. (2023). Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis. Advanced Science. 10(30). e2303908–e2303908. 33 indexed citations
9.
10.
Ni, Haiqing, Mengjia Zhu, Zhihui Kuang, et al.. (2022). IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma. Cancer Letters. 536. 215663–215663. 2 indexed citations
11.
Chen, Bingliang, Hao Li, Rui Li, et al.. (2022). Inflammatory bowel disease is associated with worse sexual function: a systematic review and meta-analysis. Translational Andrology and Urology. 11(7). 959–973. 10 indexed citations
12.
Li, Qinyu, Bingliang Chen, Kai Zeng, et al.. (2022). Integrated analysis to identify the AC005154.6/hsa-miR-29c-3p/CCNL2 axis as a novel prognostic biomarker associated with immune infiltration in prostate cancer. Cancer Cell International. 22(1). 346–346. 2 indexed citations
13.
14.
Wang, Min, Bingliang Chen, Hao Li, et al.. (2021). Lower Urinary Tract Symptoms and Sexual Dysfunction in Male: A Systematic Review and Meta-Analysis. Frontiers in Medicine. 8. 653510–653510. 7 indexed citations
15.
Kuang, Zhihui, Min Wu, Zhihai Wu, et al.. (2020). A Novel Bispecific Antibody with PD-L1–assisted OX40 Activation for Cancer Treatment. Molecular Cancer Therapeutics. 19(12). 2564–2574. 16 indexed citations
16.
Wang, Yan, Haiqing Ni, Shuaixiang Zhou, et al.. (2020). Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. Cancer Immunology Immunotherapy. 70(2). 365–376. 87 indexed citations
17.
Chen, Bingliang, et al.. (2007). Efficacy of anti-CTLA-4 antibody in the SA1N tumor model when combined with dexamethasone. Cancer Research. 67. 2202–2202. 5 indexed citations
18.
Liang, Yuxin, Xiaoyong Li, Edward J. Rebar, et al.. (2002). Activation of Vascular Endothelial Growth Factor A Transcription in Tumorigenic Glioblastoma Cell Lines by an Enhancer with Cell Type-specific DNase I Accessibility. Journal of Biological Chemistry. 277(22). 20087–20094. 30 indexed citations
19.
Liu, Peiqi, Edward J. Rebar, Lei Zhang, et al.. (2001). Regulation of an Endogenous Locus Using a Panel of Designed Zinc Finger Proteins Targeted to Accessible Chromatin Regions. Journal of Biological Chemistry. 276(14). 11323–11334. 191 indexed citations
20.
Chen, Bingliang. (1972). 'Ch'u Tz'u and shamanism in ancient China /. OhioLink ETD Center (Ohio Library and Information Network). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hui Zeng Breakdown of academic impact, for papers by Irena Radovanovic Breakdown of academic impact, for papers by Tae Hyun Hwang Breakdown of academic impact, for papers by Yalai Bai Breakdown of academic impact, for papers by Robyn D. Gartrell Breakdown of academic impact, for papers by Aibin Liang Breakdown of academic impact, for papers by Ting Zhuang Breakdown of academic impact, for papers by Anita K. Mehta Breakdown of academic impact, for papers by Julia Gilhodes Breakdown of academic impact, for papers by Yingtao Bi
Rankless by CCL
2026